carbon monoxide has been researched along with Pulmonary Hypertension in 100 studies
Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to determine whether reduced lung diffusing capacity for carbon monoxide (DLCO) predicts the presence of pulmonary hypertension (PH) in heterogeneous group of patients." | 7.76 | Does reduced lung diffusing capacity for carbon monoxide predict the presence of pulmonary hypertension? ( Alpert, M; Dabbagh, O; Delcour, KS; Jarbou, M; Singla, A, 2010) |
| "We aimed to investigate the toxicity of carbon monoxide (CO) in rats with right ventricle (RV) remodeling induced by hypoxic pulmonary hypertension (PHT)." | 7.74 | Continuous inhalation of carbon monoxide induces right ventricle ischemia and dysfunction in rats with hypoxic pulmonary hypertension. ( Antier, D; Bonnet, P; Eder, V; Gautier, M; Hanton, G; Le Net, JL, 2007) |
| "We investigated the expression of heme oxygenase-1 (HO-1) gene and production of endogenous carbon monoxide (CO) in the rat lung tissue at different time points of chronic hypoxic pulmonary hypertension and the effect of hemin on the expression of HO-1 gene and pulmonary hypertension." | 7.72 | The role of endogenous carbon monoxide in the hypoxic vascular remodeling of rat model of hypoxic pulmonary hypertension. ( Xu, Y; Zhang, Z; Zhen, G, 2003) |
| "To study the plasma level of endogenous carbon monoxide (CO) in patients with chronic cor pulmonale (CCP) and its relationship with endothelin-1 (ET-1) and hypoxic pulmonary hypertension (HPH)." | 7.71 | [A clinical study on the relationship between endogenous carbon monoxide and hypoxic pulmonary hypertension]. ( Liu, Y; Ouyang, S; Sun, P; Wang, D, 2002) |
| "To investigate the expression of heme oxygenase-1 gene and production of endogenous carbon monoxide in the rat lung tissue at different time points of chronic hypoxic pulmonary hypertension and the effect of hemin, an inducer of heme oxygenase, on the expression of HO-1 gene and production of endogenous carbon monoxide and pulmonary hypertension." | 7.71 | [The role of endogenous carbon monoxide in vascular remodeling in hypoxic pulmonary hypertension]. ( Xu, YJ; Zhang, ZX; Zhen, GH, 2002) |
| "A 49-year-old woman presented with pulmonary hypertension, profound arterial hypoxemia, and a single-breath carbon monoxide diffusing capacity (DLCO) which was 17% of predicted." | 7.67 | Pulmonary veno-occlusive disease associated with severe reduction of single-breath carbon monoxide diffusing capacity. ( Colby, TV; Crapo, RO; Elliott, CG; Hill, T, 1988) |
| "There was increased mortality in interstitial lung disease‒PH as compared with chronic obstructive pulmonary disease‒PH, but PH severity based on the WHO classification did not alter survival." | 5.51 | Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide. ( Archer, SL; Misialek, JR; Prins, KW; Pritzker, M; Rose, L; Thenappan, T; Weir, EK, 2019) |
| "Carbon monoxide (CO) has emerged as a potently protective, homeostatic molecule that prevents the development of vascular disorders when administered prophylactically." | 5.33 | Carbon monoxide reverses established pulmonary hypertension. ( Billiar, TR; Chin, BY; Czsimadia, E; Ifedigbo, E; Kanno, S; Otterbein, LE; Rao, J; Shimoda, L; Wegiel, B; Zuckerbraun, BS, 2006) |
| " Renal insufficiency, PAH associated with connective tissue disease, functional class III, mean right atrial pressure, resting systolic blood pressure and heart rate, 6-minute walk distance, brain natriuretic peptide, percent predicted carbon monoxide diffusing capacity, and pericardial effusion on echocardiogram all predicted mortality." | 5.14 | Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). ( Badesch, DB; Barst, RJ; Benza, RL; Coffey, CS; Elliott, CG; Foreman, AJ; Frantz, RP; Frost, A; Gomberg-Maitland, M; Liou, TG; McGoon, MD; Miller, DP, 2010) |
| "The aim of the study was to investigate pulmonary function parameters in patients who did and did not have pulmonary hypertension, and the roles of forced vital capacity (FVC)/diffusing capacity of the lungs for carbon monoxide (DLCO) and FVC/DLCO/alveolar volume (VA) values in patients with COPD accompanied by pulmonary hypertension." | 4.12 | Can FVC/DLCO predict pulmonary hypertension in patients with chronic obstructive pulmonary disease? ( Beyhan Sagmen, S; Fidan, A, 2022) |
| "The ratio of the diffusing capacity of the lung for carbon monoxide (DLCO) and for nitric oxide (DLNO) measured simultaneously is modified in patients with precapillary pulmonary hypertension (PH)." | 3.96 | DLNO/DLCO ratio evolution under targeted therapy in patients with pulmonary hypertension. ( Accassat, S; Bertoletti, L; Catella, J; Chapelle, C; Chomette-Ballereau, S; Costes, F; Court Fortune, I; De Magalhaes, E; Gaultier, JB; Tulane, C, 2020) |
| "This study sought to investigate the prognostic importance of a low diffusion capacity of the lung for carbon monoxide (DLCO) in patients with a catheter-based diagnosis of pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF)." | 3.83 | Diffusion Capacity and Mortality in Patients With Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction. ( Fuge, J; Hoeper, MM; Meyer, K; Olsson, KM; Rademacher, J; Welte, T, 2016) |
| "In systemic sclerosis (SSc), impaired diffusing capacity for carbon monoxide (DLCO) can indicate interstitial lung disease (ILD), pulmonary hypertension (PH), and/or other disease manifestations, including anemia." | 3.79 | Comparison of different measures of diffusing capacity for carbon monoxide (DLCO) in systemic sclerosis. ( Assayag, D; Baron, M; Caron, M; Fox, BD; Gaudreau-Taillefer, R; Hirsch, A; Hudson, M; Rudski, L; Steele, R; Tatibouet, S, 2013) |
| "The objective of this study was to determine whether reduced lung diffusing capacity for carbon monoxide (DLCO) predicts the presence of pulmonary hypertension (PH) in heterogeneous group of patients." | 3.76 | Does reduced lung diffusing capacity for carbon monoxide predict the presence of pulmonary hypertension? ( Alpert, M; Dabbagh, O; Delcour, KS; Jarbou, M; Singla, A, 2010) |
| "Chimonin can reduce pulmonary hypertension and pulmonary vessel remodeling induced by hypoxic hypercapnia through inhibiting proliferation of collagen I, the mechanism maybe is up regulating endogenous carbon monoxide system." | 3.76 | [The effect of chimonin on collagen metabolism of pulmonary arterioles in chronic hypoxic rats]. ( Huang, XY; Qian, GQ; Wang, LX; Xu, XM, 2010) |
| "We aimed to investigate the toxicity of carbon monoxide (CO) in rats with right ventricle (RV) remodeling induced by hypoxic pulmonary hypertension (PHT)." | 3.74 | Continuous inhalation of carbon monoxide induces right ventricle ischemia and dysfunction in rats with hypoxic pulmonary hypertension. ( Antier, D; Bonnet, P; Eder, V; Gautier, M; Hanton, G; Le Net, JL, 2007) |
| " They had an unusual pattern of cardiopulmonary abnormalities with mild to moderate airway obstruction, severe hypoxemia, hypocapnia, and a very low diffusing capacity for carbon monoxide (p < 0." | 3.73 | Severe pulmonary hypertension and chronic obstructive pulmonary disease. ( Bugnet, AS; Chaouat, A; Ducoloné, A; Ehrhart, M; Enache, I; Kadaoui, N; Kessler, R; Schott, R; Weitzenblum, E, 2005) |
| "We investigated the expression of heme oxygenase-1 (HO-1) gene and production of endogenous carbon monoxide (CO) in the rat lung tissue at different time points of chronic hypoxic pulmonary hypertension and the effect of hemin on the expression of HO-1 gene and pulmonary hypertension." | 3.72 | The role of endogenous carbon monoxide in the hypoxic vascular remodeling of rat model of hypoxic pulmonary hypertension. ( Xu, Y; Zhang, Z; Zhen, G, 2003) |
| "To determine whether there are factors, such as the diffusing capacity for carbon monoxide (DLCO) or pulmonary artery pressure (PAP) on echocardiogram, that can predict the development of pulmonary hypertension (PHT) in patients with limited scleroderma." | 3.72 | Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. ( Medsger, TA; Steen, V, 2003) |
| "To study the plasma level of endogenous carbon monoxide (CO) in patients with chronic cor pulmonale (CCP) and its relationship with endothelin-1 (ET-1) and hypoxic pulmonary hypertension (HPH)." | 3.71 | [A clinical study on the relationship between endogenous carbon monoxide and hypoxic pulmonary hypertension]. ( Liu, Y; Ouyang, S; Sun, P; Wang, D, 2002) |
| "To investigate the expression of heme oxygenase-1 gene and production of endogenous carbon monoxide in the rat lung tissue at different time points of chronic hypoxic pulmonary hypertension and the effect of hemin, an inducer of heme oxygenase, on the expression of HO-1 gene and production of endogenous carbon monoxide and pulmonary hypertension." | 3.71 | [The role of endogenous carbon monoxide in vascular remodeling in hypoxic pulmonary hypertension]. ( Xu, YJ; Zhang, ZX; Zhen, GH, 2002) |
| "Up-regulation of endogenous carbon monoxide system can inhibit pulmonary vessel remodeling in rats with chronic pulmonary heart disease induced by hypoxia and hypercapnia." | 3.71 | The inhibition of pulmonary vessel remodeling by carbon monoxide system in rats with chronic pulmonary heart disease. ( Chen, S; Fan, X; Huang, X; Wang, L; Wang, Q; Xu, Z, 2002) |
| "Carbon monoxide (CO) has been proposed to attenuate the vasoconstrictor response to local hypoxia that contributes to pulmonary hypertension." | 3.71 | Homogeneous segmental profile of carbon monoxide-mediated pulmonary vasodilation in rats. ( Naik, JS; Walker, BR, 2001) |
| "A 49-year-old woman presented with pulmonary hypertension, profound arterial hypoxemia, and a single-breath carbon monoxide diffusing capacity (DLCO) which was 17% of predicted." | 3.67 | Pulmonary veno-occlusive disease associated with severe reduction of single-breath carbon monoxide diffusing capacity. ( Colby, TV; Crapo, RO; Elliott, CG; Hill, T, 1988) |
| "Patients with SSc meeting the ACR/EULAR systemic sclerosis classification criteria with diffuse cutaneous SSc (dcSSc) subset per LeRoy criteria, and a disease duration of less than or equal to 18 months will be randomized to placebo or riociguat 0." | 2.84 | RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis. ( Allanore, Y; de Oliveira Pena, J; Denton, C; Distler, O; Khanna, D; Matucci-Cerinic, M; Pope, J, 2017) |
| "Patients with systemic sclerosis (SSc) do not exhibit a normal increase in the diffusing capacity for carbon monoxide (DLCO) on assuming the supine position." | 2.67 | Failure of vasoldilator infusion to alter pulmonary diffusing capacity in systemic sclerosis. ( Dole, WP; Thurm, CA; Wigley, FM; Wise, RA, 1991) |
| "Pulmonary hypertension is associated with mortality." | 2.52 | [A newly-defined entity: combined pulmonary fibrosis and emphysema syndrome]. ( Özçelik, N; Özsu, S, 2015) |
| " No study reported adverse maternal, fetal, or neonatal outcomes from the CO inhalation in association with measuring DL(CO)." | 2.46 | CO and NO pulmonary diffusing capacity during pregnancy: Safety and diagnostic potential. ( Artal, R; Blood, AB; Longo, LD; Power, GG; Vlastos, EJ; Zavorsky, GS, 2010) |
| "There was increased mortality in interstitial lung disease‒PH as compared with chronic obstructive pulmonary disease‒PH, but PH severity based on the WHO classification did not alter survival." | 1.51 | Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide. ( Archer, SL; Misialek, JR; Prins, KW; Pritzker, M; Rose, L; Thenappan, T; Weir, EK, 2019) |
| "Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease in which the amount of emphysema and airway disease may be very different between individuals, even in end-stage disease." | 1.46 | Hypoxic vascular response and ventilation/perfusion matching in end-stage COPD may depend on p22phox. ( Ghanim, B; Heschl, S; Jain, PP; Klepetko, W; Kwapiszewska, G; Marsh, LM; Nagaraj, C; Nagy, BM; Olschewski, A; Olschewski, H; Papp, R; Pienn, M; Tabeling, C; Weir, EK; Witzenrath, M, 2017) |
| "Systemic sclerosis-related interstitial lung disease (SSc-ILD) is the leading cause of death in SSc." | 1.46 | Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease. ( Béhal, H; Duhamel, A; Faivre, JB; Hachulla, AL; Hachulla, E; Hatron, PY; Lambert, M; Launay, D; Le Gouellec, N; Matran, R; Morell-Dubois, S; Perez, T; Remy-Jardin, M; Sobanski, V, 2017) |
| "A subgroup of patients with idiopathic pulmonary arterial hypertension (IPAH) has severely reduced diffusing capacity of the lung for carbon monoxide (DLCO) and poor prognosis." | 1.39 | Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses. ( Bogaard, HJ; Boonstra, A; de Man, FS; Groepenhoff, H; Grünberg, K; Leter, EM; Nossent, EJ; Trip, P; van den Berk, IA; Vonk-Noordegraaf, A; Westerhof, N, 2013) |
| "Pulmonary hypertension (PH) complicating systemic sclerosis (SSc)-related interstitial lung disease (ILD) is usually associated with a poor prognosis." | 1.37 | Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. ( Allanore, Y; Berezne, A; Bletry, O; Clerson, P; Cottin, V; Couderc, LJ; Hachulla, E; Hatron, PY; Humbert, M; Launay, D; Le Pavec, J; Mouthon, L; Yaici, A, 2011) |
| "Pulmonary hypertension was the most frequent condition associated with Kco severe reduction." | 1.37 | Conditions associated with severe carbon monoxide diffusion coefficient reduction. ( Bayle, JY; Cordier, JF; Cottin, V; Glerant, JC; Kiakouama, L; Mornex, JF, 2011) |
| "Pulmonary hypertension was found in 34." | 1.36 | [Sarcoidosis. Clinical presentation and prognosis]. ( Cáneva, J; González, EL; Vigliano, C, 2010) |
| "The vascular dysfunction was related to preeclampsia itself because siblings of offspring of mothers with preeclampsia who were born after a normal pregnancy had normal vascular function." | 1.36 | Pulmonary and systemic vascular dysfunction in young offspring of mothers with preeclampsia. ( Allemann, Y; Hutter, D; Jayet, PY; Nicod, P; Rexhaj, E; Rimoldi, SF; Salmòn, CS; Sartori, C; Sartori-Cucchia, C; Scherrer, U; Schwab, M; Stuber, T; Thalmann, S; Turini, P; Villena, M, 2010) |
| "Pulmonary hypertension was diagnosed in 10 patients (20%)." | 1.36 | Frequency of pulmonary hypertension in asymptomatic β-thalassemia major patients and the role of physiological parameters in evaluation. ( Ates, A; Balci, YI; Hacioglu, S; Kiter, G; Sari, I, 2010) |
| "Eight patients developed PAH, 29 had disease progression, and 10 died during a median followup of 29 months." | 1.35 | High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. ( Allanore, Y; Avouac, J; Borderie, D; Ekindjian, OG; Guillevin, L; Hachulla, E; Kahan, A; Meune, C; Meyer, O; Mouthon, L; Weber, S; Zerkak, D, 2008) |
| "Carbon monoxide (CO) has emerged as a potently protective, homeostatic molecule that prevents the development of vascular disorders when administered prophylactically." | 1.33 | Carbon monoxide reverses established pulmonary hypertension. ( Billiar, TR; Chin, BY; Czsimadia, E; Ifedigbo, E; Kanno, S; Otterbein, LE; Rao, J; Shimoda, L; Wegiel, B; Zuckerbraun, BS, 2006) |
| "Age and the presence of interstitial lung disease (ILD) were associated with more frequent occurrence of TG > 23 and > 33 mmHg initially and at follow-up, but were not associated with progression rate." | 1.33 | Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. ( Akesson, A; Ekman, R; Eskilsson, J; Hesselstrand, R; Isaksson, A; Ohlin, AK; Scheja, A, 2005) |
| "Hydrogen sulfide (H2S), which has been recognized as a toxic gas, can be endogenously produced in the body." | 1.33 | [Role of gasotransmitters in the pathogenesis of pulmonary hypertension]. ( Du, JB; Jin, HF; Tang, CS; Wang, YF, 2006) |
| "A total of 137 (52 with and 85 without pulmonary fibrosis) had echocardiography and lung function tests within 3 months of their definitive invasive study." | 1.32 | Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. ( Black, CM; Coghlan, JG; Davar, J; Du Bois, RM; Knight, C; Mukerjee, D; St George, D; Wells, AU, 2004) |
| "Carbon monoxide (CO) has also been proposed to influence smooth muscle tone via activation of sGC." | 1.32 | Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. ( Bloch, KD; Chang, Y; Evgenov, NV; Evgenov, OV; Falkowski, GE; Gnoth, MJ; Ichinose, F; Zapol, WM, 2004) |
| "Pulmonary hypertension was strongly associated with an initial DLCO of less than 55% of predicted normal and a FVC (% predicted)/DLCO (% predicted) ratio of greater than 1." | 1.28 | Isolated diffusing capacity reduction in systemic sclerosis. ( Conte, C; Graham, G; Medsger, TA; Owens, G; Steen, VD, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (8.00) | 18.7374 |
| 1990's | 4 (4.00) | 18.2507 |
| 2000's | 35 (35.00) | 29.6817 |
| 2010's | 44 (44.00) | 24.3611 |
| 2020's | 9 (9.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sugiyama, Y | 1 |
| Matsubara, H | 1 |
| Shimokawahara, H | 1 |
| Ogawa, A | 1 |
| Favoino, E | 1 |
| Catacchio, G | 1 |
| Mininni, A | 1 |
| Ruscitti, P | 1 |
| Riccieri, V | 1 |
| Liakouli, V | 1 |
| Corrado, A | 1 |
| Navarini, L | 1 |
| Ciccia, F | 1 |
| Cipriani, P | 1 |
| Cantatore, FP | 1 |
| Valesini, G | 1 |
| Giacomelli, R | 1 |
| Perosa, F | 1 |
| Hoeper, MM | 2 |
| Dwivedi, K | 1 |
| Pausch, C | 1 |
| Lewis, RA | 1 |
| Olsson, KM | 2 |
| Huscher, D | 1 |
| Pittrow, D | 1 |
| Grünig, E | 1 |
| Staehler, G | 1 |
| Vizza, CD | 1 |
| Gall, H | 1 |
| Distler, O | 2 |
| Opitz, C | 1 |
| Gibbs, JSR | 1 |
| Delcroix, M | 1 |
| Park, DH | 1 |
| Ghofrani, HA | 1 |
| Ewert, R | 1 |
| Kaemmerer, H | 1 |
| Kabitz, HJ | 1 |
| Skowasch, D | 1 |
| Behr, J | 1 |
| Milger, K | 1 |
| Lange, TJ | 1 |
| Wilkens, H | 1 |
| Seyfarth, HJ | 1 |
| Held, M | 1 |
| Dumitrescu, D | 1 |
| Tsangaris, I | 1 |
| Vonk-Noordegraaf, A | 3 |
| Ulrich, S | 1 |
| Klose, H | 1 |
| Claussen, M | 1 |
| Eisenmann, S | 1 |
| Schmidt, KH | 1 |
| Swift, AJ | 1 |
| Thompson, AAR | 1 |
| Elliot, CA | 1 |
| Rosenkranz, S | 1 |
| Condliffe, R | 1 |
| Kiely, DG | 1 |
| Halank, M | 1 |
| Hemnes, AR | 1 |
| Leopold, JA | 1 |
| Radeva, MK | 1 |
| Beck, GJ | 1 |
| Abidov, A | 1 |
| Aldred, MA | 1 |
| Barnard, J | 1 |
| Rosenzweig, EB | 1 |
| Borlaug, BA | 1 |
| Chung, WK | 1 |
| Comhair, SAA | 1 |
| Desai, AA | 1 |
| Dubrock, HM | 1 |
| Erzurum, SC | 2 |
| Finet, JE | 1 |
| Frantz, RP | 3 |
| Garcia, JGN | 1 |
| Geraci, MW | 1 |
| Gray, MP | 1 |
| Grunig, G | 1 |
| Hassoun, PM | 1 |
| Highland, KB | 1 |
| Hill, NS | 1 |
| Hu, B | 1 |
| Kwon, DH | 1 |
| Jacob, MS | 1 |
| Jellis, CL | 1 |
| Larive, AB | 1 |
| Lempel, JK | 1 |
| Maron, BA | 1 |
| Mathai, SC | 1 |
| McCarthy, K | 1 |
| Mehra, R | 1 |
| Nawabit, R | 1 |
| Newman, JH | 1 |
| Olman, MA | 1 |
| Park, MM | 1 |
| Ramos, JA | 1 |
| Renapurkar, RD | 1 |
| Rischard, FP | 1 |
| Sherer, SG | 1 |
| Tang, WHW | 1 |
| Thomas, JD | 1 |
| Vanderpool, RR | 1 |
| Waxman, AB | 1 |
| Wilcox, JD | 1 |
| Yuan, JX | 1 |
| Horn, EM | 1 |
| Nihtyanova, SI | 1 |
| Schreiber, BE | 1 |
| Ong, VH | 1 |
| Wells, AU | 4 |
| Coghlan, JG | 2 |
| Denton, CP | 1 |
| Beyhan Sagmen, S | 1 |
| Fidan, A | 1 |
| Shlobin, OA | 1 |
| Kouranos, V | 2 |
| Barnett, SD | 1 |
| Alhamad, EH | 1 |
| Culver, DA | 1 |
| Barney, J | 1 |
| Cordova, FC | 1 |
| Carmona, EM | 1 |
| Scholand, MB | 1 |
| Wijsenbeek, M | 1 |
| Ganesh, S | 1 |
| Lower, EE | 1 |
| Engel, PJ | 1 |
| Wort, J | 1 |
| Price, L | 1 |
| Nathan, SD | 1 |
| Baughman, RP | 1 |
| Catella, J | 1 |
| Costes, F | 1 |
| Gaultier, JB | 1 |
| Court Fortune, I | 1 |
| Tulane, C | 1 |
| De Magalhaes, E | 1 |
| Accassat, S | 1 |
| Chomette-Ballereau, S | 1 |
| Chapelle, C | 1 |
| Bertoletti, L | 1 |
| Chaouat, A | 2 |
| Adir, Y | 2 |
| Freitas, CSG | 1 |
| Baldi, BG | 1 |
| Jardim, C | 1 |
| Araujo, MS | 1 |
| Sobral, JB | 1 |
| Heiden, GI | 1 |
| Kairalla, RA | 1 |
| Souza, R | 1 |
| Carvalho, CRR | 1 |
| Nagaraj, C | 1 |
| Tabeling, C | 1 |
| Nagy, BM | 1 |
| Jain, PP | 1 |
| Marsh, LM | 1 |
| Papp, R | 1 |
| Pienn, M | 1 |
| Witzenrath, M | 1 |
| Ghanim, B | 1 |
| Klepetko, W | 1 |
| Weir, EK | 2 |
| Heschl, S | 1 |
| Kwapiszewska, G | 1 |
| Olschewski, A | 1 |
| Olschewski, H | 1 |
| Le Gouellec, N | 1 |
| Duhamel, A | 1 |
| Perez, T | 3 |
| Hachulla, AL | 1 |
| Sobanski, V | 2 |
| Faivre, JB | 1 |
| Morell-Dubois, S | 3 |
| Lambert, M | 3 |
| Hatron, PY | 4 |
| Hachulla, E | 5 |
| Béhal, H | 1 |
| Matran, R | 2 |
| Launay, D | 5 |
| Remy-Jardin, M | 3 |
| Degano, B | 1 |
| Soumagne, T | 1 |
| Delaye, T | 1 |
| Berger, P | 1 |
| Guillien, A | 1 |
| Pellegrin, JL | 1 |
| Magy-Bertrand, N | 1 |
| Agard, C | 1 |
| Tiev, KP | 1 |
| Hua-Huy, T | 1 |
| Tardiff, C | 1 |
| Diaz, V | 1 |
| Chambellan, A | 1 |
| Dinh-Xuan, AT | 1 |
| Farber, HW | 1 |
| Badesch, DB | 2 |
| Benza, RL | 2 |
| Elliott, CG | 3 |
| McGoon, MD | 2 |
| Selej, M | 1 |
| Zhao, C | 1 |
| Frost, AE | 1 |
| Wu, X | 1 |
| Xu, W | 1 |
| Wang, J | 2 |
| Tian, X | 1 |
| Tian, Z | 1 |
| Xu, K | 1 |
| Öztürk, A | 1 |
| Kayacan, O | 1 |
| Corzo, P | 1 |
| Pros, A | 1 |
| Martinez-Llorens, J | 1 |
| Molina, L | 1 |
| Ling, SF | 1 |
| Balcells, E | 1 |
| Rose, L | 1 |
| Prins, KW | 1 |
| Archer, SL | 2 |
| Pritzker, M | 1 |
| Misialek, JR | 1 |
| Thenappan, T | 2 |
| Shafran, I | 1 |
| Lang, IM | 1 |
| Ninagawa, K | 1 |
| Kato, M | 1 |
| Nakamura, H | 1 |
| Abe, N | 1 |
| Kono, M | 1 |
| Fujieda, Y | 1 |
| Oku, K | 1 |
| Yasuda, S | 1 |
| Ohira, H | 1 |
| Tsujino, I | 1 |
| Atsumi, T | 1 |
| Hudson, M | 1 |
| Assayag, D | 1 |
| Caron, M | 1 |
| Fox, BD | 1 |
| Hirsch, A | 1 |
| Steele, R | 1 |
| Gaudreau-Taillefer, R | 1 |
| Tatibouet, S | 1 |
| Rudski, L | 1 |
| Baron, M | 1 |
| Trip, P | 2 |
| Nossent, EJ | 1 |
| de Man, FS | 2 |
| van den Berk, IA | 1 |
| Boonstra, A | 2 |
| Groepenhoff, H | 1 |
| Leter, EM | 1 |
| Westerhof, N | 1 |
| Grünberg, K | 1 |
| Bogaard, HJ | 2 |
| Girerd, B | 1 |
| Garcia, G | 1 |
| Humbert, M | 3 |
| Montani, D | 1 |
| Sivova, N | 1 |
| Wémeau-Stervinou, L | 1 |
| De Groote, P | 2 |
| Denis, G | 1 |
| Lamblin, N | 1 |
| Fertin, M | 1 |
| Lefevre, G | 1 |
| Le Rouzic, O | 1 |
| Wallaert, B | 1 |
| Minai, OA | 1 |
| Fessler, H | 1 |
| Stoller, JK | 1 |
| Criner, GJ | 1 |
| Scharf, SM | 1 |
| Meli, Y | 1 |
| Nutter, B | 1 |
| DeCamp, MM | 1 |
| Abid, S | 1 |
| Houssaïni, A | 1 |
| Mouraret, N | 1 |
| Marcos, E | 1 |
| Amsellem, V | 1 |
| Wan, F | 1 |
| Dubois-Randé, JL | 1 |
| Derumeaux, G | 1 |
| Boczkowski, J | 1 |
| Motterlini, R | 1 |
| Adnot, S | 1 |
| Martinot, JB | 1 |
| Guénard, HJ | 1 |
| Mosing, M | 1 |
| Kutter, AP | 1 |
| Iff, S | 1 |
| Raszplewicz, J | 1 |
| Mauch, J | 1 |
| Bohm, SH | 1 |
| Tusman, G | 1 |
| Ollech, JE | 1 |
| Vainshelboim, B | 1 |
| Shostak, Y | 1 |
| Laor, A | 1 |
| Kramer, MR | 1 |
| Özçelik, N | 1 |
| Özsu, S | 1 |
| Adrovic, A | 1 |
| Oztunc, F | 1 |
| Barut, K | 1 |
| Koka, A | 1 |
| Gojak, R | 1 |
| Sahin, S | 1 |
| Demir, T | 1 |
| Kasapcopur, O | 1 |
| Meyer, K | 1 |
| Rademacher, J | 1 |
| Fuge, J | 1 |
| Welte, T | 1 |
| Colaci, M | 1 |
| Giuggioli, D | 1 |
| Sebastiani, M | 1 |
| Manfredi, A | 1 |
| Lumetti, F | 1 |
| Luppi, F | 1 |
| Cerri, S | 1 |
| Ferri, C | 1 |
| Pope, J | 1 |
| Denton, C | 1 |
| Allanore, Y | 3 |
| Matucci-Cerinic, M | 1 |
| de Oliveira Pena, J | 1 |
| Khanna, D | 1 |
| Takei, M | 1 |
| Kawakami, T | 1 |
| Kataoka, M | 1 |
| Kuwahira, I | 1 |
| Fukuda, K | 1 |
| Hoenicka, M | 1 |
| Schmid, C | 1 |
| Chandra, S | 1 |
| Shah, SJ | 1 |
| Rich, S | 1 |
| Gomberg-Maitland, M | 2 |
| Tzilas, V | 1 |
| Koti, A | 1 |
| Papandrinopoulou, D | 1 |
| Tsoukalas, G | 1 |
| Funauchi, M | 1 |
| Kishimoto, K | 1 |
| Kinoshita, K | 1 |
| Zavorsky, GS | 1 |
| Blood, AB | 1 |
| Power, GG | 1 |
| Longo, LD | 1 |
| Artal, R | 1 |
| Vlastos, EJ | 1 |
| Torchio, R | 1 |
| Guglielmo, M | 1 |
| Giardino, R | 1 |
| Ardissone, F | 1 |
| Ciacco, C | 1 |
| Gulotta, C | 1 |
| Veljkovic, A | 1 |
| Bugiani, M | 1 |
| Dong, MQ | 1 |
| Liu, ML | 1 |
| Xu, DQ | 1 |
| Luo, Y | 1 |
| Zhang, B | 1 |
| Liu, LL | 1 |
| Xu, M | 1 |
| Zhao, PT | 1 |
| Gao, YQ | 1 |
| Li, ZC | 1 |
| Delcour, KS | 1 |
| Singla, A | 1 |
| Jarbou, M | 1 |
| Alpert, M | 1 |
| Dabbagh, O | 1 |
| Miller, DP | 1 |
| Foreman, AJ | 1 |
| Coffey, CS | 1 |
| Frost, A | 1 |
| Barst, RJ | 1 |
| Liou, TG | 1 |
| Jayet, PY | 1 |
| Rimoldi, SF | 1 |
| Stuber, T | 1 |
| Salmòn, CS | 1 |
| Hutter, D | 1 |
| Rexhaj, E | 1 |
| Thalmann, S | 1 |
| Schwab, M | 1 |
| Turini, P | 1 |
| Sartori-Cucchia, C | 1 |
| Nicod, P | 1 |
| Villena, M | 1 |
| Allemann, Y | 1 |
| Scherrer, U | 1 |
| Sartori, C | 1 |
| Huang, XY | 1 |
| Xu, XM | 1 |
| Qian, GQ | 1 |
| Wang, LX | 1 |
| Kiter, G | 1 |
| Balci, YI | 1 |
| Ates, A | 1 |
| Hacioglu, S | 1 |
| Sari, I | 1 |
| Johnson, DC | 1 |
| Hesselstrand, R | 2 |
| Wildt, M | 1 |
| Ekmehag, B | 1 |
| Wuttge, DM | 1 |
| Scheja, A | 2 |
| González, EL | 1 |
| Vigliano, C | 1 |
| Cáneva, J | 1 |
| Zhen, GH | 1 |
| Zhang, ZX | 1 |
| Xu, YJ | 1 |
| Spillers, JG | 1 |
| Llanos, AJ | 2 |
| Ebensperger, G | 1 |
| Herrera, EA | 2 |
| Reyes, RV | 1 |
| Pulgar, VM | 1 |
| Serón-Ferré, M | 1 |
| Díaz, M | 1 |
| Parer, JT | 1 |
| Giussani, DA | 1 |
| Moraga, FA | 1 |
| Riquelme, RA | 2 |
| Kiakouama, L | 1 |
| Cottin, V | 3 |
| Glerant, JC | 1 |
| Bayle, JY | 1 |
| Mornex, JF | 1 |
| Cordier, JF | 2 |
| Berezne, A | 1 |
| Couderc, LJ | 1 |
| Bletry, O | 1 |
| Yaici, A | 1 |
| Mouthon, L | 3 |
| Le Pavec, J | 1 |
| Clerson, P | 1 |
| Harari, S | 1 |
| Mal, H | 1 |
| Dorfmüller, P | 1 |
| Jaïs, X | 1 |
| Reynaud-Gaubert, M | 1 |
| Prevot, G | 1 |
| Lazor, R | 1 |
| Taillé, C | 1 |
| Lacronique, J | 1 |
| Zeghmar, S | 1 |
| Simonneau, G | 1 |
| Rapti, A | 1 |
| Gialafos, E | 1 |
| Aggeli, K | 1 |
| Moyssakis, J | 1 |
| Kallianos, A | 1 |
| Kostopoulos, C | 1 |
| Anagnostopoulou, O | 1 |
| Sfikakis, PP | 1 |
| Tzelepis, GE | 1 |
| Liu, Y | 1 |
| Sun, P | 1 |
| Ouyang, S | 1 |
| Wang, D | 1 |
| Huang, X | 1 |
| Wang, L | 1 |
| Chen, S | 1 |
| Xu, Z | 1 |
| Wang, Q | 1 |
| Fan, X | 1 |
| Steen, V | 1 |
| Medsger, TA | 2 |
| Zhen, G | 1 |
| Zhang, Z | 1 |
| Xu, Y | 1 |
| Mukerjee, D | 1 |
| St George, D | 1 |
| Knight, C | 1 |
| Davar, J | 1 |
| Du Bois, RM | 1 |
| Black, CM | 1 |
| Qi, J | 1 |
| Du, J | 1 |
| Tang, X | 1 |
| Li, J | 1 |
| Wei, B | 1 |
| Tang, C | 1 |
| Qingyou, Z | 1 |
| Junbao, D | 1 |
| Weijin, Z | 1 |
| Hui, Y | 1 |
| Chaoshu, T | 1 |
| Chunyu, Z | 1 |
| Suematsu, M | 1 |
| Machado, RF | 1 |
| Londhe Nerkar, MV | 1 |
| Dweik, RA | 1 |
| Hammel, J | 1 |
| Janocha, A | 1 |
| Pyle, J | 1 |
| Laskowski, D | 1 |
| Jennings, C | 1 |
| Arroliga, AC | 1 |
| Evgenov, OV | 1 |
| Ichinose, F | 1 |
| Evgenov, NV | 1 |
| Gnoth, MJ | 1 |
| Falkowski, GE | 1 |
| Chang, Y | 1 |
| Bloch, KD | 1 |
| Zapol, WM | 1 |
| Ekman, R | 1 |
| Eskilsson, J | 1 |
| Isaksson, A | 1 |
| Ohlin, AK | 1 |
| Akesson, A | 1 |
| Dubuis, E | 1 |
| Potier, M | 1 |
| Wang, R | 1 |
| Vandier, C | 1 |
| Bugnet, AS | 1 |
| Kadaoui, N | 1 |
| Schott, R | 1 |
| Enache, I | 1 |
| Ducoloné, A | 1 |
| Ehrhart, M | 1 |
| Kessler, R | 1 |
| Weitzenblum, E | 1 |
| Jin, HF | 3 |
| Du, JB | 5 |
| Tang, CS | 5 |
| Zhang, QY | 1 |
| Zhang, CY | 1 |
| Huang, XL | 1 |
| Ling, YQ | 1 |
| Zhu, TN | 1 |
| Zhang, JL | 1 |
| Ling, YL | 1 |
| Vitali, SH | 1 |
| Mitsialis, SA | 1 |
| Christou, H | 1 |
| Fernandez-Gonzalez, A | 1 |
| Liu, X | 1 |
| Kourembanas, S | 1 |
| van der Lee, I | 1 |
| Zanen, P | 1 |
| Grutters, JC | 1 |
| Snijder, RJ | 1 |
| van den Bosch, JMM | 1 |
| Li, XH | 2 |
| Ding, YG | 1 |
| Bu, DF | 2 |
| Tang, XY | 2 |
| Wang, YF | 1 |
| Zuckerbraun, BS | 1 |
| Chin, BY | 1 |
| Wegiel, B | 1 |
| Billiar, TR | 1 |
| Czsimadia, E | 1 |
| Rao, J | 1 |
| Shimoda, L | 1 |
| Ifedigbo, E | 1 |
| Kanno, S | 1 |
| Otterbein, LE | 1 |
| Pagnoux, C | 1 |
| Queyrel, V | 1 |
| Guillevin, L | 2 |
| Gautier, M | 1 |
| Antier, D | 1 |
| Bonnet, P | 1 |
| Le Net, JL | 1 |
| Hanton, G | 1 |
| Eder, V | 1 |
| Quadrelli, S | 1 |
| Ciallella, L | 1 |
| Catalán Pellet, AC | 1 |
| Molinari, L | 1 |
| Salvado, A | 1 |
| Auad, C | 1 |
| Spina, JC | 1 |
| Borderie, D | 1 |
| Avouac, J | 1 |
| Zerkak, D | 1 |
| Meune, C | 1 |
| Meyer, O | 1 |
| Ekindjian, OG | 1 |
| Weber, S | 1 |
| Kahan, A | 1 |
| Tian, Y | 1 |
| Bourbonnais, JM | 1 |
| Samavati, L | 1 |
| Widimský, J | 2 |
| Tartulier, M | 1 |
| Zielinski, J | 1 |
| Frídl, P | 1 |
| Friebe, A | 1 |
| Malkewitz, J | 1 |
| Schultz, G | 1 |
| Koesling, D | 1 |
| Borland, C | 1 |
| Cox, Y | 1 |
| Higenbottam, T | 2 |
| Nachar, RA | 1 |
| Pastene, CM | 1 |
| Sanhueza, EM | 1 |
| Troncoso, S | 1 |
| Naik, JS | 1 |
| Walker, BR | 1 |
| Carraway, MS | 1 |
| Ghio, AJ | 1 |
| Suliman, HB | 1 |
| Carter, JD | 1 |
| Whorton, AR | 1 |
| Piantadosi, CA | 1 |
| Anderson, FL | 1 |
| Tsagaris, TJ | 1 |
| Jubiz, W | 1 |
| Kuida, H | 1 |
| Steen, VD | 1 |
| Graham, G | 1 |
| Conte, C | 1 |
| Owens, G | 1 |
| Thurm, CA | 1 |
| Wigley, FM | 1 |
| Dole, WP | 1 |
| Wise, RA | 1 |
| Corriveau, ML | 1 |
| Rosen, BJ | 1 |
| Keller, CA | 1 |
| Chun, DS | 1 |
| Dolan, GF | 1 |
| Otulana, B | 1 |
| Colby, TV | 1 |
| Hill, T | 1 |
| Crapo, RO | 1 |
| Burrows, B | 1 |
| Jebavý, P | 1 |
| Hurych, J | 1 |
| Stanĕk, V | 1 |
| Dunnill, MS | 1 |
| Allison, PR | 1 |
| Marshall, R | 1 |
| Morrell, MT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension[NCT01347216] | 12,000 participants (Anticipated) | Observational | 2007-07-01 | Recruiting | |||
| Redefining Pulmonary Hypertension Through Pulmonary Vascular Disease Phenomics (PVDOMICS)[NCT02980887] | 1,195 participants (Actual) | Observational | 2016-11-30 | Active, not recruiting | |||
| Cardiopulmonary Interactions in Patients With Heart Failure (Kardio-pulmonale Interaktionen Bei Patienten Mit Linksherzerkrankungen)[NCT03317314] | 0 participants (Actual) | Observational | 2017-07-01 | Withdrawn (stopped due to Study was considered not useful and competing with another study in clinical context) | |||
| A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)[NCT02283762] | Phase 2 | 121 participants (Actual) | Interventional | 2015-01-15 | Completed | ||
| High Intensity Respiratory Muscle Training as a Pre-habilitation in Lung Surgery[NCT04826575] | 150 participants (Anticipated) | Interventional | 2021-03-25 | Recruiting | |||
| Use of Non-invasive Measurement of Cardiac Output and Stroke Volume to Assess Risk and Response to Treatment in Patients With PAH or CTEPH[NCT05618093] | 100 participants (Anticipated) | Interventional | 2023-03-02 | Enrolling by invitation | |||
| Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study[NCT03655704] | Early Phase 1 | 7 participants (Actual) | Interventional | 2019-08-22 | Completed | ||
| REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management[NCT00370214] | 3,515 participants (Actual) | Observational | 2006-03-31 | Completed | |||
| National, Prospective, Multicenter,Observational Registry Study on Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension in China[NCT01417338] | 3,079 participants (Anticipated) | Observational | 2009-08-31 | Recruiting | |||
| Placebo Controlled Trial of Bosentan vs Placebo in NYHA Class I/II Scleroderma Patients With Exercise Induced Pulmonary Hypertension[NCT00377455] | Phase 2 | 5 participants (Actual) | Interventional | 2006-09-30 | Terminated (stopped due to Study was terminated due to inadequate enrolment) | ||
| Chronisch Obstruktive Lungenerkrankung Und Pulmonale Hypertonie: Prävalenz Und Lebensqualität[NCT01423071] | 220 participants (Actual) | Observational | 2011-08-31 | Completed | |||
| A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Dose Study to Determine the Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension (PAH)[NCT01725256] | Phase 2 | 29 participants (Actual) | Interventional | 2012-11-30 | Terminated (stopped due to Terminated early dt to acquisition of Sponsor and change in corporate priorities) | ||
| A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension[NCT01725269] | Phase 2 | 17 participants (Actual) | Interventional | 2013-03-31 | Terminated (stopped due to Terminated early dt acquisition of Sponsor and change in corporate priorities) | ||
| Changes in Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide After Allogeneic Versus Autologous Hematopoietic Stem-cell Transplantation[NCT01735526] | 40 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Negative change in FVC percent predicted indicates worsening. (NCT02283762)
Timeframe: Baseline to week 52
| Intervention | FVC percent predicted (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521) | -2.376 |
| Placebo | -2.945 |
The mRSS is a validated physical examination method for estimating skin thickness. It correlates with biopsy measures of collagen in the dermis and reflects prognosis and visceral involvement, especially in early disease. It is scored on 0 (normal) to 3+ (severe induration) ordinal scales over 17 body areas, with a maximum score of 51 (higher score means worse situation) and is used to categorize severity of SSc. A decrease in the mean change of mRSS shows mRSS improved. (NCT02283762)
Timeframe: Baseline to week 52
| Intervention | score on a scale (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521) | -2.088 |
| Placebo | -0.769 |
The HAQ-DI is a composite measure from which a 'Standard Disability Index' score can be computed to assess a patient's disability level. Generally, a score of 0-1 represents mild to moderate difficulty, 1-2 moderate to severe disability and 2-3 severe to very severe disability. The HAQ-DI comprises 20 items that assess patient abilities across 8 functional activities: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item is rated on a 4-point scale: 0=Without ANY difficulty, 1=With SOME difficulty, 2=With MUCH difficulty, 3=UNABLE to do. The 8 scores of the 8 sections are summed and divided by 8. In the event that one section is not completed by a subject then the summed score would be divided by 7. The final overall HAQ-DI score ranges from 0 to 3 and positive change indicates worse health-related quality of life (HRQoL). (NCT02283762)
Timeframe: Baseline to week 52
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline | |
| Placebo | 0.693 | 0.127 |
| Riociguat (Adempas, BAY63-2521) | 0.888 | 0.054 |
The patient's global assessments (a self-report) quantified the overall disease activity or severity of SSc, with scores ranging from 0 (good) to 10 (worse). Positive change in the patient's global assessments score indicates worsening. (NCT02283762)
Timeframe: Baseline to week 52
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline | |
| Placebo | 3.770 | -0.022 |
| Riociguat (Adempas, BAY63-2521) | 3.933 | 0.689 |
The physician's global assessments (reported by the physician) quantified the overall disease activity or severity of SSc, with scores ranging from 0 (good) to 10 (worse). Positive change in the physician's global assessments score indicates worsening. (NCT02283762)
Timeframe: Baseline to week 52
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline | |
| Placebo | 4.016 | -0.745 |
| Riociguat (Adempas, BAY63-2521) | 4.333 | -0.067 |
CRISS forms a composite response index consisting of SSc-related organ involvement and the following five variables: mRSS, FVC percent predicted, physician's and patient's global assessments, and HAQ-DI score (from SHAQ patient-reported outcome). The resulting index is a 2-step process that captures clinically meaningful worsening of internal organ involvement and the core variables that show change. Patients for whom the predicted CRISS probability was ≥ 0.60 were considered improved, while patients for whom the predicted probability was < 0.60 were considered not improved. (NCT02283762)
Timeframe: Week 52
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| CRISS probability ≥ 0.60 | CRISS probability < 0.60 | |
| Placebo | 11 | 50 |
| Riociguat (Adempas, BAY63-2521) | 11 | 49 |
9 reviews available for carbon monoxide and Pulmonary Hypertension
| Article | Year |
|---|---|
[A newly-defined entity: combined pulmonary fibrosis and emphysema syndrome].
Topics: Aged, 80 and over; Carbon Monoxide; Humans; Hypertension, Pulmonary; Lung; Male; Pulmonary Emphysema | 2015 |
Cardiovascular effects of modulators of soluble guanylyl cyclase activity.
Topics: Animals; Atherosclerosis; Carbon Monoxide; Cardiovascular Agents; Cyclic GMP; Guanylate Cyclase; Hum | 2008 |
Prognostic factors in idiopathic pulmonary fibrosis.
Topics: Carbon Monoxide; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Oxygen; Prognosis; | 2009 |
[Early diagnosis of connective tissue disease-related pulmonary hypertension].
Topics: Biomarkers; Carbon Monoxide; Chronic Disease; Connective Tissue Diseases; Early Diagnosis; Echocardi | 2009 |
CO and NO pulmonary diffusing capacity during pregnancy: Safety and diagnostic potential.
Topics: Carbon Monoxide; Female; Humans; Hypertension, Pulmonary; Nitric Oxide; Pregnancy; Pregnancy Complic | 2010 |
[CO-mediated regulation of vascular function and hypertensive disorders].
Topics: Animals; Carbon Monoxide; Cyclic GMP; Cytochrome P-450 Enzyme System; Ferritins; Guanylate Cyclase; | 2004 |
[Significance of gaseous signal molecule in the pathogenesis of cardiovascular diseases].
Topics: Animals; Carbon Monoxide; Cardiovascular Diseases; Humans; Hydrogen Sulfide; Hypertension; Hypertens | 2005 |
[The role of gasotransmitters in the pathogenesis of hypoxic pulmonary hypertension].
Topics: Animals; Carbon Monoxide; Humans; Hydrogen Sulfide; Hypertension, Pulmonary; Hypoxia; Nitric Oxide | 2008 |
Arterial oxygenation and pulmonary hemodynamics in patients with chronic airways obstruction.
Topics: Blood Pressure; Carbon Monoxide; Cardiac Output; Chronic Disease; Hemodynamics; Humans; Hypertension | 1974 |
3 trials available for carbon monoxide and Pulmonary Hypertension
88 other studies available for carbon monoxide and Pulmonary Hypertension
| Article | Year |
|---|---|
Outcome of mean pulmonary arterial pressure-based intensive treatment for patients with pulmonary arterial hypertension.
Topics: Arterial Pressure; Carbon Monoxide; Familial Primary Pulmonary Hypertension; Hemodynamics; Humans; H | 2022 |
Novel biomarker for pulmonary vascular disease in systemic sclerosis patients.
Topics: Biomarkers; Carbon Monoxide; Humans; Hypertension, Pulmonary; Pulmonary Fibrosis; Scleroderma, Syste | 2022 |
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis.
Topics: Carbon Monoxide; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; M | 2022 |
Clinical Characteristics and Transplant-Free Survival Across the Spectrum of Pulmonary Vascular Disease.
Topics: Carbon Monoxide; Cross-Sectional Studies; Humans; Hypertension, Pulmonary; Pulmonary Circulation; Va | 2022 |
Dynamic Prediction of Pulmonary Hypertension in Systemic Sclerosis Using Landmark Analysis.
Topics: Carbon Monoxide; Female; Humans; Hypertension, Pulmonary; Lung; Male; Scleroderma, Systemic; Vital C | 2023 |
Can FVC/DLCO predict pulmonary hypertension in patients with chronic obstructive pulmonary disease?
Topics: Carbon Monoxide; Humans; Hypertension, Pulmonary; Oxygen; Pulmonary Disease, Chronic Obstructive; Vi | 2022 |
Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry.
Topics: Aged; Carbon Monoxide; Cardiac Catheterization; Female; Forced Expiratory Volume; Hemodynamics; Huma | 2020 |
DLNO/DLCO ratio evolution under targeted therapy in patients with pulmonary hypertension.
Topics: Aged; Antihypertensive Agents; Carbon Monoxide; Endothelin Receptor Antagonists; Epoprostenol; Femal | 2020 |
Diffusing Capacity for Carbon Monoxide Is a Reflection of the Pulmonary Microcirculation, but Not Only.
Topics: Carbon Monoxide; Humans; Hypertension, Pulmonary; Microcirculation; Pulmonary Diffusing Capacity; Pu | 2020 |
Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method.
Topics: Adult; Carbon Monoxide; Echocardiography; Female; Humans; Hypertension, Pulmonary; Lymphangioleiomyo | 2017 |
Hypoxic vascular response and ventilation/perfusion matching in end-stage COPD may depend on p22phox.
Topics: Adult; Animals; Carbon Monoxide; Case-Control Studies; Cytochrome b Group; Female; Humans; Hypertens | 2017 |
Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carbon Monoxide; Cyclophosphamide; Diffusion; Echocardio | 2017 |
Combined measurement of carbon monoxide and nitric oxide lung transfer does not improve the identification of pulmonary hypertension in systemic sclerosis.
Topics: Adult; Blood-Air Barrier; Capillary Permeability; Carbon Monoxide; Early Diagnosis; Early Medical In | 2017 |
Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL.
Topics: Adult; Aged; Carbon Monoxide; Female; Guideline Adherence; Humans; Hypertension, Pulmonary; Hypoxia; | 2018 |
Clinical characteristics in lymphangioleiomyomatosis-related pulmonary hypertension: an observation on 50 patients.
Topics: Adult; Carbon Monoxide; Echocardiography; Exercise Test; Female; Hemodynamics; Humans; Hypertension, | 2019 |
Rising stars of DPLD survival: FVC and exercise desaturation (a single-center study)
Topics: Age Factors; Aged; Blood Pressure; Carbon Monoxide; Connective Tissue Diseases; Exercise; Exercise T | 2018 |
Isolated DLco/VA reduction in systemic sclerosis patients: a new patient subset?
Topics: Aged; Carbon Monoxide; Case-Control Studies; Echocardiography; Female; Humans; Hypertension, Pulmona | 2018 |
Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide.
Topics: Aged; Carbon Monoxide; Chronic Disease; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; | 2019 |
Diffusion capacity of the lung-a disease biomarker linking ventilation and circulation.
Topics: Biomarkers; Carbon Monoxide; Humans; Hypertension, Pulmonary; Lung; Lung Diseases | 2019 |
Reduced diffusing capacity for carbon monoxide predicts borderline pulmonary arterial pressure in patients with systemic sclerosis.
Topics: Aged; Algorithms; Arterial Pressure; Carbon Monoxide; Cross-Sectional Studies; Female; Humans; Hyper | 2019 |
Comparison of different measures of diffusing capacity for carbon monoxide (DLCO) in systemic sclerosis.
Topics: Aged; Carbon Monoxide; Cohort Studies; Female; Humans; Hypertension, Pulmonary; Lung; Lung Diseases, | 2013 |
Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses.
Topics: Adult; Aged; Carbon Monoxide; Coronary Artery Disease; Familial Primary Pulmonary Hypertension; Fema | 2013 |
Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension.
Topics: Adult; Bone Morphogenetic Protein Receptors, Type II; Carbon Monoxide; Comorbidity; Female; France; | 2014 |
Relevance of partitioning DLCO to detect pulmonary hypertension in systemic sclerosis.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Female; Humans; Hypertension, Pulmonary; Lung Disea | 2013 |
Clinical characteristics and prediction of pulmonary hypertension in severe emphysema.
Topics: Aged; Carbon Monoxide; Comorbidity; Echocardiography, Doppler; Female; Forced Expiratory Volume; Hum | 2014 |
P21-dependent protective effects of a carbon monoxide-releasing molecule-3 in pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Apoptosis; Arterial Pressure; Carbon Monoxide; Cell Proliferation; | 2014 |
TLNO/TLCO ratio is not the end of the road.
Topics: Carbon Monoxide; Cohort Studies; Diffusion; Gases; Hemoglobins; Humans; Hypertension, Pulmonary; Nit | 2014 |
The effects of cardiac output and pulmonary arterial hypertension on volumetric capnography derived-variables during normoxia and hypoxia.
Topics: Anesthesia; Animals; Capnography; Carbon Monoxide; Cardiac Output; Dobutamine; Hemodynamics; Hyperte | 2015 |
The effect of pulmonary hypertension on aerobic exercise capacity in lung transplant candidates with advanced emphysema.
Topics: Aged; Carbon Monoxide; Cardiac Catheterization; Exercise Test; Exercise Tolerance; Forced Expiratory | 2015 |
The frequency of pulmonary hypertension in patients with juvenile scleroderma.
Topics: Adolescent; Age of Onset; Arterial Pressure; Carbon Monoxide; Child; Child, Preschool; Echocardiogra | 2015 |
Diffusion Capacity and Mortality in Patients With Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Carbon Monoxide; Female; Heart Failure; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate | 2016 |
Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline.
Topics: Adult; Aged; Antibodies, Antinuclear; Autoantibodies; Biomarkers; Carbon Monoxide; Female; Follow-Up | 2015 |
Elucidating the Ventilation/Perfusion Mismatch and Reduction of Diffusing Capacity for Carbon Monoxide in Chronic Thromboembolic Pulmonary Hypertension.
Topics: Angioplasty; Carbon Monoxide; Humans; Hypertension, Pulmonary; Lung; Pulmonary Diffusing Capacity | 2017 |
Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension.
Topics: Adult; Aged; Biomarkers; Carbon Monoxide; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged | 2010 |
Exercise ventilatory inefficiency and mortality in patients with chronic obstructive pulmonary disease undergoing surgery for non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Carcinoma, Non-Small-Cell Lung; Exercise Test; Fema | 2010 |
Tanshinone IIA modulates pulmonary vascular response to agonist and hypoxia primarily via inhibiting Ca2+ influx and release in normal and hypoxic pulmonary hypertension rats.
Topics: Abietanes; Animals; Calcium; Carbon Monoxide; Endothelium, Vascular; Extracellular Space; Hypertensi | 2010 |
Does reduced lung diffusing capacity for carbon monoxide predict the presence of pulmonary hypertension?
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Female; Humans; Hypertension, Pulmonary; Lung; Male | 2010 |
Pulmonary and systemic vascular dysfunction in young offspring of mothers with preeclampsia.
Topics: Adolescent; Age Factors; Carbon Monoxide; Child; Echocardiography, Doppler; Female; Humans; Hyperten | 2010 |
[The effect of chimonin on collagen metabolism of pulmonary arterioles in chronic hypoxic rats].
Topics: Animals; Arterioles; Carbon Monoxide; Chronic Disease; Collagen Type I; Collagen Type III; Drugs, Ch | 2010 |
Frequency of pulmonary hypertension in asymptomatic β-thalassemia major patients and the role of physiological parameters in evaluation.
Topics: Adolescent; Adult; beta-Thalassemia; Carbon Monoxide; Child; Diffusion; Female; Humans; Hypertension | 2010 |
Association of chronic mountain sickness with abnormal pulmonary microcirculation: importance of adjusting predicted diffusing capacity of the lung for carbon monoxide for altitude, hemoglobin, and lung volume.
Topics: Altitude; Altitude Sickness; Carbon Monoxide; Exercise; Humans; Hypertension, Pulmonary; Microcircul | 2010 |
Survival in patients with pulmonary arterial hypertension associated with systemic sclerosis from a Swedish single centre: prognosis still poor and prediction difficult.
Topics: Adult; Aged; Blood Pressure; Carbon Monoxide; Case-Control Studies; Female; Humans; Hypertension, Pu | 2011 |
[Sarcoidosis. Clinical presentation and prognosis].
Topics: Adult; Aged; Argentina; Carbon Monoxide; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; | 2010 |
[The role of endogenous carbon monoxide in vascular remodeling in hypoxic pulmonary hypertension].
Topics: Animals; Carbon Monoxide; Heme Oxygenase (Decyclizing); Hemin; Hypertension, Pulmonary; Hypoxia; Mal | 2002 |
Carbon monoxide or nitric oxide: which came first?
Topics: Administration, Inhalation; Aged; Antimetabolites; Carbon Monoxide; Endothelium-Dependent Relaxing F | 2011 |
Fetal and postnatal pulmonary circulation in the Alto Andino.
Topics: Altitude; Animals; Animals, Newborn; Blood Pressure; Camelids, New World; Carbon Monoxide; Fetus; He | 2011 |
Conditions associated with severe carbon monoxide diffusion coefficient reduction.
Topics: Adult; Aged; Aged, 80 and over; Airway Resistance; Blood Flow Velocity; Carbon Monoxide; Female; Hum | 2011 |
Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.
Topics: Adult; Aged; Antibodies, Antinuclear; Blood Pressure; Carbon Monoxide; Comorbidity; Cross-Sectional | 2011 |
Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients.
Topics: Adult; Breath Tests; Carbon Monoxide; Cardiac Catheterization; Exercise Test; Female; Hemodynamics; | 2012 |
Elevated pulmonary arterial systolic pressure in patients with sarcoidosis: prevalence and risk factors.
Topics: Adult; Aged; Arterial Pressure; Biomarkers; Carbon Monoxide; Comorbidity; Cross-Sectional Studies; F | 2013 |
[A clinical study on the relationship between endogenous carbon monoxide and hypoxic pulmonary hypertension].
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Endothelin-1; Female; Humans; Hypertension, Pulmona | 2002 |
The inhibition of pulmonary vessel remodeling by carbon monoxide system in rats with chronic pulmonary heart disease.
Topics: Animals; Carbon Monoxide; Hypercapnia; Hypertension, Pulmonary; Hypoxia; Pulmonary Heart Disease; Ra | 2002 |
Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement.
Topics: Adult; Autoantibodies; Carbon Monoxide; Case-Control Studies; Centromere; Diffusion; Echocardiograph | 2003 |
The role of endogenous carbon monoxide in the hypoxic vascular remodeling of rat model of hypoxic pulmonary hypertension.
Topics: Animals; Carbon Monoxide; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Hypertension, Pulmonary; H | 2003 |
Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis.
Topics: Aged; Blood Pressure; Carbon Monoxide; Cardiac Catheterization; Humans; Hypertension, Pulmonary; Mas | 2004 |
The upregulation of endothelial nitric oxide synthase and urotensin-II is associated with pulmonary hypertension and vascular diseases in rats produced by aortocaval shunting.
Topics: Animals; Arteriovenous Shunt, Surgical; Carbon Monoxide; Endothelium, Vascular; Heme Oxygenase (Decy | 2004 |
Impact of hydrogen sulfide on carbon monoxide/heme oxygenase pathway in the pathogenesis of hypoxic pulmonary hypertension.
Topics: Alkynes; Animals; Blood Pressure; Carbon Monoxide; Cells, Cultured; Cystathionine gamma-Lyase; Enzym | 2004 |
Nitric oxide and pulmonary arterial pressures in pulmonary hypertension.
Topics: Blood Pressure; Carbon Monoxide; Female; Humans; Hypertension, Pulmonary; Middle Aged; Nitric Oxide; | 2004 |
Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Administration, Inhalation; Anim | 2004 |
Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001.
Topics: Age Factors; Blood Pressure; Calcitonin Gene-Related Peptide; Carbon Monoxide; Echocardiography, Dop | 2005 |
Continuous inhalation of carbon monoxide attenuates hypoxic pulmonary hypertension development presumably through activation of BKCa channels.
Topics: Animals; Calcium; Carbon Monoxide; Cell Polarity; Chronic Disease; Drug Administration Schedule; Hem | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
[The regulation of carbon monoxide/heme oxygenase system by hydrogen sulfide in rats with hypoxic pulmonary hypertension].
Topics: Animals; Carbon Monoxide; Heme Oxygenase (Decyclizing); Hydrogen Sulfide; Hypertension, Pulmonary; H | 2004 |
Multiple factors contributing to lipopolysaccharide-induced reactivity changes in rabbit pulmonary artery.
Topics: Acetylcysteine; Animals; Carbon Monoxide; Hypertension, Pulmonary; Lipopolysaccharides; Male; Nitric | 2005 |
Mechanisms of heme oxygenase-1-mediated cardiac and pulmonary vascular protection in chronic hypoxia: roles of carbon monoxide and bilirubin.
Topics: Animals; Bilirubin; Biliverdine; Carbon Monoxide; Chronic Disease; Heme Oxygenase-1; Hypertension, P | 2005 |
Diffusing capacity for nitric oxide and carbon monoxide in patients with diffuse parenchymal lung disease and pulmonary arterial hypertension.
Topics: Adult; Carbon Monoxide; Female; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Male; | 2006 |
[Impact of hydrogen sulfide donor on experimental pulmonary hypertension induced by high pulmonary flow and endogenous carbon monoxide/heme oxygenase pathway].
Topics: Animals; Carbon Monoxide; Heme Oxygenase (Decyclizing); Hypertension, Pulmonary; Lung; Male; Myocyte | 2006 |
[Role of gasotransmitters in the pathogenesis of pulmonary hypertension].
Topics: Animals; Blood Flow Velocity; Carbon Monoxide; Humans; Hydrogen Sulfide; Hypertension, Pulmonary; Hy | 2006 |
Sodium hydrosulfide alleviated pulmonary vascular structural remodeling induced by high pulmonary blood flow in rats.
Topics: Animals; Arteriovenous Shunt, Surgical; Carbon Monoxide; Extracellular Signal-Regulated MAP Kinases; | 2006 |
Carbon monoxide reverses established pulmonary hypertension.
Topics: Animals; Apoptosis; Carbon Monoxide; Cells, Cultured; Disease Models, Animal; Hemodynamics; Humans; | 2006 |
Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease.
Topics: Adult; Carbon Monoxide; Comorbidity; Dyspnea; Female; Humans; Hypertension, Pulmonary; Lung Diseases | 2007 |
Continuous inhalation of carbon monoxide induces right ventricle ischemia and dysfunction in rats with hypoxic pulmonary hypertension.
Topics: Administration, Inhalation; Animals; Blood Flow Velocity; Blood Pressure; Carbon Monoxide; Carboxyhe | 2007 |
[Lung involvement in systemic sclerosis].
Topics: Adolescent; Adult; Aged; Biomarkers; Carbon Monoxide; Child; DNA Topoisomerases, Type I; Female; Hum | 2007 |
High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.
Topics: Adult; Aged; Biomarkers; Capillaries; Carbon Monoxide; Comorbidity; Diffusion; Disease Progression; | 2008 |
Clinical predictors of pulmonary hypertension in sarcoidosis.
Topics: Adult; Carbon Monoxide; Echocardiography; Exercise Test; Female; Humans; Hypertension, Pulmonary; Ma | 2008 |
Prediction of pulmonary hypertension from postural changes of pulmonary transfer factor.
Topics: Blood Pressure; Carbon Monoxide; Gravitation; Humans; Hypertension, Pulmonary; Lung Diseases, Obstru | 1984 |
Positive effects of pollution.
Topics: Air Pollutants; Animals; Carbon Monoxide; Cattle; Cyclic GMP; Enzyme Activation; Guanylate Cyclase; | 1996 |
Reduction of pulmonary capillary blood volume in patients with severe unexplained pulmonary hypertension.
Topics: Adult; Blood Volume; Breath Tests; Capillaries; Carbon Monoxide; Female; Humans; Hypertension, Pulmo | 1996 |
Low-dose inhaled carbon monoxide reduces pulmonary vascular resistance during acute hypoxemia in adult sheep.
Topics: Administration, Inhalation; Animals; Blood Gas Analysis; Carbon Monoxide; Carboxyhemoglobin; Cardiac | 2001 |
Homogeneous segmental profile of carbon monoxide-mediated pulmonary vasodilation in rats.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Carbon Monoxide; Cyclic | 2001 |
Carbon monoxide promotes hypoxic pulmonary vascular remodeling.
Topics: Actins; Animals; Apoptosis; Atmospheric Pressure; Carbon Monoxide; Cell Division; DNA, Single-Strand | 2002 |
Prostaglandin F and E levels during endotoxin-induced pulmonary hypertension in calves.
Topics: Animals; Blood Pressure; Carbon Monoxide; Cardiac Output; Cattle; Endotoxins; Hypertension, Pulmonar | 1975 |
Isolated diffusing capacity reduction in systemic sclerosis.
Topics: Carbon Monoxide; Female; Humans; Hypertension, Pulmonary; Middle Aged; Predictive Value of Tests; Pr | 1992 |
Effect of posture, hydralazine, and nifedipine on hemodynamics, ventilation, and gas exchange in patients with chronic obstructive pulmonary disease.
Topics: Carbon Dioxide; Carbon Monoxide; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Lung Di | 1988 |
The role of physiological deadspace and shunt in the gas exchange of patients with pulmonary hypertension: a study of exercise and prostacyclin infusion.
Topics: Adolescent; Adult; Carbon Dioxide; Carbon Monoxide; Cardiac Output; Epoprostenol; Female; Humans; Hy | 1988 |
Pulmonary veno-occlusive disease associated with severe reduction of single-breath carbon monoxide diffusing capacity.
Topics: Carbon Monoxide; Female; Humans; Hypertension, Pulmonary; Lung; Middle Aged; Pulmonary Diffusing Cap | 1988 |
Relationship between orthostatic changes of pulmonary diffusing capacity and haemodynamics of lesser circulation.
Topics: Blood Pressure; Carbon Monoxide; Cardiac Output; Catheterization; Diffusion; Heart; Heart Rate; Hemo | 1971 |
Pulmonary embolism.
Topics: Animals; Blood Platelets; Bronchospirometry; Carbon Monoxide; Diffusion; Dogs; Hospitals; Hypertensi | 1967 |